Sun Pharma Q4 Results: Adjusted net profit rises 4.8% YoY; check final dividend, record date, and what Dilip Shanghvi said

Its total revenue from operations came in at ₹12,958.84 crore, up 8.1% against ₹11,982.90 crore registered in the corresponding quarter of the previous fiscal.

The pharma major said in its press release that its India formulation sales stood at ₹4,213 crore, up 13.6%, while US formulation sales came in at US$464 million, down 2.5%.

Further, the company's Global Specialty sales were at US$295 million, up 8.6%, accounting for 19.9% of Q4 FY25 sales, and Emerging Markets formulation sales stood at US$261 million, up 6.3% YoY.

Moreover, the press release added that its Rest of World formulation sales came in at US$ 200 million, up 2.0% YoY.

Sun Pharma added that its R&D investments during the quarter under review stood at ₹816.6 crore.

On the operational front, Sun Pharma said that its operating profit, or EBITDA (earnings before interest, taxes, depreciation, and amortisation), stood at ₹3,716.1 crore, up 22.4% YoY. This includes other operating revenues.

EBITDA margin came in at 28.7%. The margin was 25.3% in the year-ago period.

Sun Pharma's adjusted net profit (excluding the exceptional items) for Q4 FY25 was ₹2,889.1 crore, up 4.8% YoY. Reported net profit for the quarter slipped 19% YoY to ₹2,149.9 crore as against ₹2,654.6 crore logged during Q4 FY24.

Sun Pharma Q4 Results: FY25 Highlights

The pharma said that its gross sales during the fiscal year 2024-25 stood at ₹52,041.2 crore, up 9%, while India formulation sales saw a growth of 13.7% YoY at ₹16,923 crore.

EBITDA came in at ₹15,271.7 crore (including other operating revenues), up 17.3%, with a resulting EBITDA margin of 29%.

Adjusted net profit (excluding the exceptional items) for FY25 was ₹11,984.4 crore, up 19.0%. Reported net profit for FY25 was ₹10,929 crore as compared to ₹9,576.4 crore during FY24.

For the full year FY25, external Active Pharmaceutical Ingredients (API) sales were at ₹2,129.2 crore, up 11% over the same period last year. External sales of API were at ₹533 crore for Q4 FY25, up 28.2%. Sun’s API portfolio supports its formulation business and API customers across geographies.

Sun Pharma Q4 Results: Dividend details

Sun Pharma, in its press release, said that its board has recommended a final dividend of ₹5.50 per equity share of ₹1 each, subject to the shareholders' approval at the ensuing annual general meeting (AGM) of the company.

Sun Pharma has fixed Monday, July 7, 2025, as the Record Date for the purpose of determining the Members eligible to receive the final dividend, which, if approved at the Annual General Meeting to be held on July 31, 2025, shall be paid on or before Friday, August 8, 2025.

Sun Pharma Q4 Results: What Chairman Said

Dilip Shanghvi, Chairman and Managing Director of the company, said, "Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The near-term pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care. We look forward to Specialty becoming an increasingly important part of our business."

The results were announced post-market hours on Thursday. Shares of the company had settled at ₹1,724.70 apiece on the NSE, down 0.41%.